Phase 1WithdrawnINTERVENTIONAL
Study of Exenatide Once-Weekly Suspension in Chinese Patients With Type 2 Diabetes Mellitus
ClinicalTrials.gov · NCT04001231 · Registry updated: 2020-06-04
- Condition / research focus
- Type 2 Diabetes
- Sponsor
- AstraZeneca
- Countries with listed sites
- No country reported
- Registry dates and results
- Start: 2020-06-30. Completion: 2021-07-02 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Exenatide Once-Weekly Suspension (drug)
Where the study takes place — 0 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
The registry does not list facilities in this record. This does not mean the study has no sites.